Abiopharma

🔍 Lindborg Stacy (Director)

Company: Imunon, Inc. (IMNN)

Report Date: 2025-09-06

Detailed Transactions and Holdings:

• Acquired 1,667 shares of Common Stock (Direct)
  Date: 2025-09-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,584.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-06 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 234.00
• Sold 1,667 shares of Restricted Stock (Derivative)
  Date: 2025-09-06 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024.
• F2: Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock.
• F3: On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.
• REMARKS: On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person. On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.